Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon's lead product candidate, SILENOR™ (doxepin hydrochloride), has completed Phase III clinical trials for the treatment of insomnia.
When was Somaxon's initial public offering (IPO)?
December 2005
Does Somaxon pay a dividend on its common stock?
As an emerging specialty pharmaceutical company, Somaxon has not declared a cash dividend on its common stock, nor does it presently have any plans to initiate a dividend program.
Does Somaxon have a direct stock purchase program?
Somaxon does not have a direct stock purchase program.
How many shares of common stock does Somaxon have outstanding?
As of December 31, 2007, Somaxon had 18,433,000 common shares outstanding.
When does Somaxon's fiscal year end?
Somaxon's fiscal year ends on December 31st.
How many people does Somaxon employ?
Somaxon has approximately 35 employees as of January 1, 2008.
Who is Somaxon's stock transfer agent?
American Stock Transfer, who may be reached at 59 Maiden Lane, New York, NY 10038, (212) 936-5100.
Somaxon is located in Del Mar, California. The address of Somaxon is:
Somaxon Pharmaceuticals, Inc.
3721 Valley Centre Drive
Suite 500
San Diego, CA 92130
What is Somaxon's ticker symbol?
Somaxon's ticker symbol is SOMX and trades on the Nasdaq stock market.
When is Somaxon's next Annual Meeting of Stockholders?
Somaxon held its Annual Meeting on May 31, 2007. The date of the 2008 Annual Meeting is to be announced.
Who can I contact for information about my shares, transfer of my shares, change of address or lost stock certificates?
Somaxon's transfer agent is American Stock Transfer, located at 59 Maiden Lane, New York, NY 10038. They may be reached at (212) 936-5100.
Who are the members of your senior management team?
Click here to access a directory of our management team.
Who is on your Board of Directors?
Click here to access a directory of our Board of Directors
At what stage in development are your drug compounds?
Click here for a discussion of Somaxon's product development program.
Where can I find information on participating in a clinical trial?
People interested in clinical trial participation should discuss this option with their physician.
Has Somaxon submitted the NDA for SILENOR™?
Yes. On January 31, 2008, Somaxon submitted NDA 022036 for SILENOR™
Has the NDA been accepted by the FDA?
On April 14, 2008, the FDA notified Somaxon that the NDA for SILENOR™ (doxepin HCl tablets) was accepted for filing as of March 31, 2008. The PDUFA action date is December 1, 2008.
Do you have another question that hasn't been answered?
Please submit your question using the form below. Fields marked with an * are required.
